MedDataX Logo

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

NCT ID: NCT00975195

Last Updated: 2015-02-10

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

2488 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomised study to be conducted in patients with severe to very severe Chronic Obstructive Pulmonary Disease (COPD) to establish whether there is a need for these patients to be continuously treated with an inhaled corticosteroid on top of two potent long-acting bronchodilators. The study also aims to identify the type of patients who are likely to benefit from inhaled corticosteroid maintenance therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01331694

Pulmonary Disease, Chronic Obstructive
COMPLETED

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

NCT00239421

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE4

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE3

Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPD

NCT01393145

Chronic Obstructive Pulmonary Disease COPD
WITHDRAWN PHASE3

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01168310

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fluticasone high dose

fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate

Group Type EXPERIMENTAL

tiotropium inhalation

Intervention Type DRUG

salmeterol xinafoate

Intervention Type DRUG

fluticasone propionate

Intervention Type DRUG

fluticasone medium & low doses

fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate

Group Type EXPERIMENTAL

tiotropium inhalation

Intervention Type DRUG

salmeterol xinafoate

Intervention Type DRUG

fluticasone propionate

Intervention Type DRUG

placebo matched for fluticasone propionate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tiotropium inhalation

Intervention Type DRUG

salmeterol xinafoate

Intervention Type DRUG

fluticasone propionate

Intervention Type DRUG

placebo matched for fluticasone propionate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female aged 40 years or more
2. Severe to very severe chronic obstructive pulmonary disease (COPD)
3. Current or ex-smoker with smoking history of at least 10 pack years
4. At least one documented exacerbation of COPD in previous year

Exclusion Criteria

1. Significant diseases other than COPD; significant alcohol or drug abuse
2. Current clinical diagnosis of asthma requiring steroid treatment
3. History of thoracotomy with pulmonary resection
4. Regular use of daytime oxygen
5. Recent history (within 3 months) of myocardial infarction
6. Recent (within 6 weeks) respiratory infection or COPD exacerbation
7. Recent (within 6 weeks) treatment with systemic corticosteroids at doses in excess of 5milligram / day
8. Recent (within 3 months) unstable or life-threatening cardiac arrhythmia requiring intervention
9. Recent (within 1 year) hospitalisation for cardiac failure
10. Malignancy requiring chemotherapy or radiotherapy
11. Clinical diagnosis of bronchiectasis
12. Pregnant or nursing women
13. Known hypersensitivity to study drugs
14. Current or recent (within 30 days) participation in another clinical study
15. Current participation in or recent completion (within 4 weeks) of a pulmonary rehabilitation program
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

352.2046.61006 Boehringer Ingelheim Investigational Site

Concord, New South Wales, Australia

Site Status

352.2046.61001 Boehringer Ingelheim Investigational Site

Glebe, New South Wales, Australia

Site Status

352.2046.61002 Boehringer Ingelheim Investigational Site

Westmead, New South Wales, Australia

Site Status

352.2046.61004 Boehringer Ingelheim Investigational Site

Daw Park, South Australia, Australia

Site Status

352.2046.61003 Boehringer Ingelheim Investigational Site

Toorak Gardens, South Australia, Australia

Site Status

352.2046.61005 Boehringer Ingelheim Investigational Site

Woodville, South Australia, Australia

Site Status

352.2046.32002 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

352.2046.32016 Boehringer Ingelheim Investigational Site

Brussels, , Belgium

Site Status

352.2046.32015 Boehringer Ingelheim Investigational Site

Eupen, , Belgium

Site Status

352.2046.32017 Boehringer Ingelheim Investigational Site

Gilly, , Belgium

Site Status

352.2046.32014 Boehringer Ingelheim Investigational Site

Herentals, , Belgium

Site Status

352.2046.32006 Boehringer Ingelheim Investigational Site

Jambes, , Belgium

Site Status

352.2046.32008 Boehringer Ingelheim Investigational Site

Lebbeke, , Belgium

Site Status

352.2046.32001 Boehringer Ingelheim Investigational Site

Leuven, , Belgium

Site Status

352.2046.32004 Boehringer Ingelheim Investigational Site

Middelheim, , Belgium

Site Status

352.2046.32010 Boehringer Ingelheim Investigational Site

Montigny-le-Tilleul, , Belgium

Site Status

352.2046.32013 Boehringer Ingelheim Investigational Site

Turnhout, , Belgium

Site Status

352.2046.55002 Boehringer Ingelheim Investigational Site

Goiânia, , Brazil

Site Status

352.2046.55005 Boehringer Ingelheim Investigational Site

Goiânia, , Brazil

Site Status

352.2046.55001 Boehringer Ingelheim Investigational Site

Porto Alegre, , Brazil

Site Status

352.2046.55006 Boehringer Ingelheim Investigational Site

Porto Alegre, , Brazil

Site Status

352.2046.55003 Boehringer Ingelheim Investigational Site

São Paulo, , Brazil

Site Status

352.2046.35905 Boehringer Ingelheim Investigational Site

Burgas, , Bulgaria

Site Status

352.2046.35902 Boehringer Ingelheim Investigational Site

Rousse, , Bulgaria

Site Status

352.2046.35904 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

352.2046.35906 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

352.2046.35907 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

352.2046.35908 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

352.2046.35903 Boehringer Ingelheim Investigational Site

Stara Zagora, , Bulgaria

Site Status

352.2046.35909 Boehringer Ingelheim Investigational Site

Veliko Tarnovo, , Bulgaria

Site Status

352.2046.86002 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

352.2046.86003 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

352.2046.86006 Boehringer Ingelheim Investigational Site

Beijing, , China

Site Status

352.2046.86008 Boehringer Ingelheim Investigational Site

Chongqing, , China

Site Status

352.2046.86001 Boehringer Ingelheim Investigational Site

Guangzhou, , China

Site Status

352.2046.86004 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

352.2046.86005 Boehringer Ingelheim Investigational Site

Shanghai, , China

Site Status

352.2046.86007 Boehringer Ingelheim Investigational Site

Wuhan, , China

Site Status

352.2046.45001 Boehringer Ingelheim Investigational Site

Aarhus C, , Denmark

Site Status

352.2046.45003 Boehringer Ingelheim Investigational Site

København NV, , Denmark

Site Status

352.2046.45002 Boehringer Ingelheim Investigational Site

Odense C, , Denmark

Site Status

352.2046.3317A Boehringer Ingelheim Investigational Site

Brest, , France

Site Status

352.2046.3317B Boehringer Ingelheim Investigational Site

Brest, , France

Site Status

352.2046.3317C Boehringer Ingelheim Investigational Site

Brest, , France

Site Status

352.2046.3320A Boehringer Ingelheim Investigational Site

Castelnau-le-Lez, , France

Site Status

352.2046.3320B Boehringer Ingelheim Investigational Site

Castelnau-le-Lez, , France

Site Status

352.2046.3320C Boehringer Ingelheim Investigational Site

Castelnau-le-Lez, , France

Site Status

352.2046.3335A Boehringer Ingelheim Investigational Site

Clermont-Ferrand, , France

Site Status

352.2046.3314A Boehringer Ingelheim Investigational Site

Forbach, , France

Site Status

352.2046.3301A Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

352.2046.3333A Boehringer Ingelheim Investigational Site

Marseille, , France

Site Status

352.2046.3326A Boehringer Ingelheim Investigational Site

Montpellier, , France

Site Status

352.2046.3326C Boehringer Ingelheim Investigational Site

Montpellier, , France

Site Status

352.2046.3325A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

352.2046.3325C Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

352.2046.3325D Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

352.2046.3334A Boehringer Ingelheim Investigational Site

Nantes, , France

Site Status

352.2046.3324A Boehringer Ingelheim Investigational Site

Nîmes, , France

Site Status

352.2046.3332A Boehringer Ingelheim Investigational Site

Nîmes, , France

Site Status

352.2046.3332B Boehringer Ingelheim Investigational Site

Nîmes, , France

Site Status

352.2046.3332C Boehringer Ingelheim Investigational Site

Nîmes, , France

Site Status

352.2046.3331A Boehringer Ingelheim Investigational Site

Perpignan, , France

Site Status

352.2046.3331B Boehringer Ingelheim Investigational Site

Perpignan, , France

Site Status

352.2046.3331C Boehringer Ingelheim Investigational Site

Perpignan, , France

Site Status

352.2046.3329A Boehringer Ingelheim Investigational Site

Saint-Laurent-du-Var, , France

Site Status

352.2046.3329B Boehringer Ingelheim Investigational Site

Saint-Laurent-du-Var, , France

Site Status

352.2046.3302A Boehringer Ingelheim Investigational Site

Saint-Pierre, , France

Site Status

352.2046.3302B Boehringer Ingelheim Investigational Site

Saint-Pierre, , France

Site Status

352.2046.3302C Boehringer Ingelheim Investigational Site

Saint-Pierre, , France

Site Status

352.2046.3302D Boehringer Ingelheim Investigational Site

Saint-Pierre, , France

Site Status

352.2046.3336A Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

352.2046.3336B Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

352.2046.3336C Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

352.2046.3337A Boehringer Ingelheim Investigational Site

Toulouse, , France

Site Status

352.2046.49012 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

352.2046.49020 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

352.2046.49021 Boehringer Ingelheim Investigational Site

Berlin, , Germany

Site Status

352.2046.49008 Boehringer Ingelheim Investigational Site

Bochum, , Germany

Site Status

352.2046.49003 Boehringer Ingelheim Investigational Site

Cologne, , Germany

Site Status

352.2046.49019 Boehringer Ingelheim Investigational Site

Cottbus, , Germany

Site Status

352.2046.49002 Boehringer Ingelheim Investigational Site

Donaustauf, , Germany

Site Status

352.2046.49013 Boehringer Ingelheim Investigational Site

Frankfurt, , Germany

Site Status

352.2046.49025 Boehringer Ingelheim Investigational Site

Frankfurt, , Germany

Site Status

352.2046.49023 Boehringer Ingelheim Investigational Site

Frankfurt am Main, , Germany

Site Status

352.2046.49024 Boehringer Ingelheim Investigational Site

Geesthacht, , Germany

Site Status

352.2046.49022 Boehringer Ingelheim Investigational Site

Gelnhausen, , Germany

Site Status

352.2046.49001 Boehringer Ingelheim Investigational Site

Großhansdorf, , Germany

Site Status

352.2046.49006 Boehringer Ingelheim Investigational Site

Heidelberg, , Germany

Site Status

352.2046.49014 Boehringer Ingelheim Investigational Site

Immenhausen, , Germany

Site Status

352.2046.49016 Boehringer Ingelheim Investigational Site

Kiel, , Germany

Site Status

352.2046.49004 Boehringer Ingelheim Investigational Site

Mainz, , Germany

Site Status

352.2046.49005 Boehringer Ingelheim Investigational Site

Marburg, , Germany

Site Status

352.2046.49015 Boehringer Ingelheim Investigational Site

München, , Germany

Site Status

352.2046.30003 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30004 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30005 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30007 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30008 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30011 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30012 Boehringer Ingelheim Investigational Site

Athens, , Greece

Site Status

352.2046.30006 Boehringer Ingelheim Investigational Site

Heraklion, , Greece

Site Status

352.2046.30009 Boehringer Ingelheim Investigational Site

Larissa, , Greece

Site Status

352.2046.30001 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

352.2046.30002 Boehringer Ingelheim Investigational Site

Thessaloniki, , Greece

Site Status

352.2046.36003 Boehringer Ingelheim Investigational Site

Cegléd, , Hungary

Site Status

352.2046.36002 Boehringer Ingelheim Investigational Site

Deszk, , Hungary

Site Status

352.2046.36004 Boehringer Ingelheim Investigational Site

Komárom, , Hungary

Site Status

352.2046.36006 Boehringer Ingelheim Investigational Site

Pécs, , Hungary

Site Status

352.2046.36001 Boehringer Ingelheim Investigational Site

Szarvas, , Hungary

Site Status

352.2046.36005 Boehringer Ingelheim Investigational Site

Százhalombatta, , Hungary

Site Status

352.2046.36011 Boehringer Ingelheim Investigational Site

Szigetszentmiklós, , Hungary

Site Status

352.2046.39002 Boehringer Ingelheim Investigational Site

Catania, , Italy

Site Status

352.2046.39007 Boehringer Ingelheim Investigational Site

Cona, , Italy

Site Status

352.2046.39005 Boehringer Ingelheim Investigational Site

Foggia, , Italy

Site Status

352.2046.39003 Boehringer Ingelheim Investigational Site

Modena, , Italy

Site Status

352.2046.39006 Boehringer Ingelheim Investigational Site

Montescano (pv), , Italy

Site Status

352.2046.39001 Boehringer Ingelheim Investigational Site

Pisa, , Italy

Site Status

352.2046.39004 Boehringer Ingelheim Investigational Site

Sesto S. Giovanni (mi), , Italy

Site Status

352.2046.39008 Boehringer Ingelheim Investigational Site

Tradate (va), , Italy

Site Status

352.2046.31004 Boehringer Ingelheim Investigational Site

Heerlen, , Netherlands

Site Status

352.2046.31001 Boehringer Ingelheim Investigational Site

Leeuwarden, , Netherlands

Site Status

352.2046.31003 Boehringer Ingelheim Investigational Site

Rotterdam, , Netherlands

Site Status

352.2046.31002 Boehringer Ingelheim Investigational Site

Veldhoven, , Netherlands

Site Status

352.2046.64007 Boehringer Ingelheim Investigational Site

Auckland NZ, , New Zealand

Site Status

352.2046.64003 Boehringer Ingelheim Investigational Site

Christchurch, , New Zealand

Site Status

352.2046.64004 Boehringer Ingelheim Investigational Site

Dunedin, , New Zealand

Site Status

352.2046.64006 Boehringer Ingelheim Investigational Site

Hamilton, , New Zealand

Site Status

352.2046.64001 Boehringer Ingelheim Investigational Site

Newtown Wellington NZ, , New Zealand

Site Status

352.2046.64005 Boehringer Ingelheim Investigational Site

Otahuhu New Zealand, , New Zealand

Site Status

352.2046.64002 Boehringer Ingelheim Investigational Site

Tauranga, , New Zealand

Site Status

352.2046.63001 Boehringer Ingelheim Investigational Site

Caloocan, , Philippines

Site Status

352.2046.63009 Boehringer Ingelheim Investigational Site

City of Muntinlupa, , Philippines

Site Status

352.2046.63003 Boehringer Ingelheim Investigational Site

Manila, , Philippines

Site Status

352.2046.63004 Boehringer Ingelheim Investigational Site

Manila, , Philippines

Site Status

352.2046.63005 Boehringer Ingelheim Investigational Site

Quezon, , Philippines

Site Status

352.2046.63007 Boehringer Ingelheim Investigational Site

Quezon, , Philippines

Site Status

352.2046.63006 Boehringer Ingelheim Investigational Site

Quezon City, , Philippines

Site Status

352.2046.63008 Boehringer Ingelheim Investigational Site

Quezon City, , Philippines

Site Status

352.2046.48006 Boehringer Ingelheim Investigational Site

Bytom, , Poland

Site Status

352.2046.48003 Boehringer Ingelheim Investigational Site

Ostrow Wielkopolska, , Poland

Site Status

352.2046.48001 Boehringer Ingelheim Investigational Site

Poznan, , Poland

Site Status

352.2046.48002 Boehringer Ingelheim Investigational Site

Poznan, , Poland

Site Status

352.2046.48009 Boehringer Ingelheim Investigational Site

Rzeszów, , Poland

Site Status

352.2046.48011 Boehringer Ingelheim Investigational Site

Tarnowskie Góry, , Poland

Site Status

352.2046.48005 Boehringer Ingelheim Investigational Site

Warsaw, , Poland

Site Status

352.2046.48007 Boehringer Ingelheim Investigational Site

Wroclaw, , Poland

Site Status

352.2046.07006 Boehringer Ingelheim Investigational Site

Ivanovo, , Russia

Site Status

352.2046.07008 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

352.2046.07009 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

352.2046.07001 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

352.2046.07002 Boehringer Ingelheim Investigational Site

Samara, , Russia

Site Status

352.2046.07003 Boehringer Ingelheim Investigational Site

Saratov, , Russia

Site Status

352.2046.07004 Boehringer Ingelheim Investigational Site

Yaroslavl, , Russia

Site Status

352.2046.07005 Boehringer Ingelheim Investigational Site

Yaroslavl, , Russia

Site Status

352.2046.07011 Boehringer Ingelheim Investigational Site

Yekaterinburg, , Russia

Site Status

352.2046.27002 Boehringer Ingelheim Investigational Site

Bellville, , South Africa

Site Status

352.2046.27001 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

352.2046.27003 Boehringer Ingelheim Investigational Site

Cape Town, , South Africa

Site Status

352.2046.27006 Boehringer Ingelheim Investigational Site

eManzimtoti, , South Africa

Site Status

352.2046.27007 Boehringer Ingelheim Investigational Site

Pretoria, , South Africa

Site Status

352.2046.27005 Boehringer Ingelheim Investigational Site

Somerset West, , South Africa

Site Status

352.2046.27004 Boehringer Ingelheim Investigational Site

Tygerberg, , South Africa

Site Status

352.2046.34008 Boehringer Ingelheim Investigational Site

Badajoz, , Spain

Site Status

352.2046.34002 Boehringer Ingelheim Investigational Site

Barakaldo (Bilbao), , Spain

Site Status

352.2046.34001 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

352.2046.34004 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

352.2046.34009 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat, , Spain

Site Status

352.2046.34006 Boehringer Ingelheim Investigational Site

Palma de Mallorca, , Spain

Site Status

352.2046.34010 Boehringer Ingelheim Investigational Site

Pozuelo de Alarcón, , Spain

Site Status

352.2046.34013 Boehringer Ingelheim Investigational Site

Salt (Girona), , Spain

Site Status

352.2046.34011 Boehringer Ingelheim Investigational Site

Seville, , Spain

Site Status

352.2046.88607 Boehringer Ingelheim Investigational Site

Dawan, , Taiwan

Site Status

352.2046.88608 Boehringer Ingelheim Investigational Site

Dawan, , Taiwan

Site Status

352.2046.88606 Boehringer Ingelheim Investigational Site

Kaohsiung City, , Taiwan

Site Status

352.2046.88604 Boehringer Ingelheim Investigational Site

Taichung, , Taiwan

Site Status

352.2046.88601 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

352.2046.88603 Boehringer Ingelheim Investigational Site

Taipei, , Taiwan

Site Status

352.2046.2161A Boehringer Ingelheim Investigational Site

Aryanah, , Tunisia

Site Status

352.2046.2162A Boehringer Ingelheim Investigational Site

Aryanah, , Tunisia

Site Status

352.2046.2165A Boehringer Ingelheim Investigational Site

Sfax, , Tunisia

Site Status

352.2046.2164A Boehringer Ingelheim Investigational Site

Sousse, , Tunisia

Site Status

352.2046.2163A Boehringer Ingelheim Investigational Site

Tunis, , Tunisia

Site Status

352.2046.90009 Boehringer Ingelheim Investigational Site

Ankara, , Turkey (Türkiye)

Site Status

352.2046.90019 Boehringer Ingelheim Investigational Site

Ankara, , Turkey (Türkiye)

Site Status

352.2046.90016 Boehringer Ingelheim Investigational Site

Bursa, , Turkey (Türkiye)

Site Status

352.2046.90010 Boehringer Ingelheim Investigational Site

Denizli, , Turkey (Türkiye)

Site Status

352.2046.90003 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

352.2046.90004 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

352.2046.90006 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

352.2046.90008 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

352.2046.90012 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

352.2046.90017 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

352.2046.90011 Boehringer Ingelheim Investigational Site

Izmir, , Turkey (Türkiye)

Site Status

352.2046.90014 Boehringer Ingelheim Investigational Site

Izmir, , Turkey (Türkiye)

Site Status

352.2046.90018 Boehringer Ingelheim Investigational Site

Izmir, , Turkey (Türkiye)

Site Status

352.2046.90005 Boehringer Ingelheim Investigational Site

İzmit, , Turkey (Türkiye)

Site Status

352.2046.90007 Boehringer Ingelheim Investigational Site

Kayseri, , Turkey (Türkiye)

Site Status

352.2046.90001 Boehringer Ingelheim Investigational Site

Mersin, , Turkey (Türkiye)

Site Status

352.2046.90002 Boehringer Ingelheim Investigational Site

Samsun, , Turkey (Türkiye)

Site Status

352.2046.38007 Boehringer Ingelheim Investigational Site

Ivano-Frankivsk, , Ukraine

Site Status

352.2046.38002 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

352.2046.38003 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

352.2046.38004 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

352.2046.38006 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

352.2046.38005 Boehringer Ingelheim Investigational Site

Vinnitsa, , Ukraine

Site Status

352.2046.38001 Boehringer Ingelheim Investigational Site

Vinnytsia, , Ukraine

Site Status

352.2046.44008 Boehringer Ingelheim Investigational Site

Baillieston, Glasgow, , United Kingdom

Site Status

352.2046.44009 Boehringer Ingelheim Investigational Site

Barnsley, , United Kingdom

Site Status

352.2046.44018 Boehringer Ingelheim Investigational Site

Belfast, , United Kingdom

Site Status

352.2046.44010 Boehringer Ingelheim Investigational Site

Birmingham, , United Kingdom

Site Status

352.2046.44003 Boehringer Ingelheim Investigational Site

Cambridge, , United Kingdom

Site Status

352.2046.44026 Boehringer Ingelheim Investigational Site

Chertsey, , United Kingdom

Site Status

352.2046.44006 Boehringer Ingelheim Investigational Site

Chesterfield, , United Kingdom

Site Status

352.2046.44012 Boehringer Ingelheim Investigational Site

Cottingham, Hull, , United Kingdom

Site Status

352.2046.44028 Boehringer Ingelheim Investigational Site

Inverness, , United Kingdom

Site Status

352.2046.44016 Boehringer Ingelheim Investigational Site

Isleworth, , United Kingdom

Site Status

352.2046.44002 Boehringer Ingelheim Investigational Site

Liverpool, , United Kingdom

Site Status

352.2046.44001 Boehringer Ingelheim Investigational Site

London, , United Kingdom

Site Status

352.2046.44017 Boehringer Ingelheim Investigational Site

Norwich, , United Kingdom

Site Status

352.2046.44021 Boehringer Ingelheim Investigational Site

Sheffield, , United Kingdom

Site Status

352.2046.44019 Boehringer Ingelheim Investigational Site

Sunderland, , United Kingdom

Site Status

352.2046.44025 Boehringer Ingelheim Investigational Site

Windsor, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Belgium Brazil Bulgaria China Denmark France Germany Greece Hungary Italy Netherlands New Zealand Philippines Poland Russia South Africa Spain Taiwan Tunisia Turkey (Türkiye) Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials. Respir Res. 2020 Sep 17;21(1):240. doi: 10.1186/s12931-020-01482-1.

Reference Type DERIVED
PMID: 32943047 (View on PubMed)

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

Reference Type DERIVED
PMID: 30545350 (View on PubMed)

Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016 May;4(5):390-8. doi: 10.1016/S2213-2600(16)00100-4. Epub 2016 Apr 7.

Reference Type DERIVED
PMID: 27066739 (View on PubMed)

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.

Reference Type DERIVED
PMID: 25196117 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-002522-29

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

352.2046

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity
NCT00274573 COMPLETED PHASE3
Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02172469 COMPLETED PHASE3
Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD
NCT00535366 COMPLETED PHASE2
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo
NCT01072149 COMPLETED PHASE3
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01908140 COMPLETED PHASE3
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
NCT01978145 COMPLETED PHASE3
Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD
NCT01213693 COMPLETED NA
A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
NCT00239434 COMPLETED PHASE3
Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation
NCT01381458 COMPLETED
Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00274092 COMPLETED PHASE3
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
NCT01342913 COMPLETED PHASE3
The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD
NCT00559312 COMPLETED NA
A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02731846 WITHDRAWN PHASE3
Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease
NCT02172443 COMPLETED PHASE3
A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease
NCT00403286 COMPLETED PHASE2
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01053988 COMPLETED PHASE3
Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
NCT03590379 COMPLETED PHASE2
Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
NCT00523991 COMPLETED PHASE4
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604 COMPLETED PHASE2
Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)
NCT02173691 COMPLETED PHASE3
Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care
NCT00440687 COMPLETED PHASE4
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00268216 COMPLETED PHASE3
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01009463 COMPLETED PHASE3
A Study Evaluating Systemic Exposure and Pharmacodynamics in Patients With Chronic Obstructive Pulmonary Disease
NCT00774761 COMPLETED PHASE2
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01017952 COMPLETED PHASE3